<DOC>
	<DOC>NCT00259402</DOC>
	<brief_summary>- To determine the activity and efficacy of the schema specified as dose regimen - To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU</brief_summary>
	<brief_title>Oxaliplatin in Esophagus Cancer (Advanced) 1st Line</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>ECOG 01 Patients with histologically proven epidermoid carcinoma or adenocarcinoma of esophagus or stomach, with unresectable or metastatic disease; No previous treatment with chemotherapy or radiotherapy Measurable lesion (uni or bidimensional) Creatinin clearance &lt;50 mL/min Total bilirubin &gt;1.5*ULN (Upper Limit of Normal) AST/ALT &gt; 2.5*ULN Total White Blood Cell &lt;1.500.000/mL Platelet count &lt;100.000.000/mL symptomatic sensitive peripheral neuropathy pregnant or breastfeeding women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>